The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 54, Issue 1, 2006, Pages 61-63

  Menter, Alan ^a,b,g   Cather, Jennifer C ^b   Baker, Diane ^c   Farber, Harold F ^d   Lebwohl, Mark ^e   Darif, Mohamed ^f  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Baker Allergy   (United States)

^d Clinical Pharmacology Department   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f BIOGEN   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT;

CHRONIC DISEASE; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSORIASIS; RECOMBINANT FUSION PROTEINS; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 29244464655     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.10.006     Document Type: Article

References (10)

1. G.G. Krueger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, C.N. Ellis for the Alefacept Clinical Study Group A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833
2. M. Lebwohl, N. Christophers, R. Langley, J.P. Ortonne, J. Roberts, C.E. Griffiths for the Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
3. K.B. Gordon, and R.G. Langley Remittive effects of intramuscular alefacept in psoriasis J Drugs Dermatol 2 2003 624 628
4. C.S. Carlin, S.R. Feldman, J.G. Krueger, A. Menter, and G.G. Krueger A 50% reduction in the Psoriasis Area and Severity Index (PASI) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
5. C.N. Ellis, M.M. Mordin, and E.Y. Adler Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial Am J Clin Dermatol 4 2003 131 139
6. A.Y. Finlay, M.S. Salek, J. Haney for the Alefacept Clinical Study Group Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis Dermatology 206 2003 307 315
7. S.R. Feldman, A. Menter, and J.Y. Koo Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis Br J Dermatol 150 2004 317 326
8. N.J. Lowe, J. Gonzalez, J. Bagel, I. Caro, C.N. Ellis, and A. Menter Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy Int J Dermatol 42 2003 224 230
9. Menter A, Cather JC. Long-term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC.
10. C.N. Ellis, G.G. Krueger for the Alefacept Clinical Study Group Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255